关键词： 印度 强制许可 拜耳
2013年3月5日讯 /生物谷BIOON/ --大型制药公司在与印度政府之间的强制许可斗争中受到了沉重打击。印度专利上诉委员会周一裁定，印度本土仿制药生产商可以继续生产和销售拜耳（Bayer）抗癌药物多吉美（Nexavar）的仿制药。这是有史以来印度专利机构首次证实，在印度使用强制许可是合法的。
拜耳立即发表声明，表示将对该项裁决提起上诉。而无国界医生组织（MSF）则对裁决表示欢迎，称该项裁决树立了一个重要的先例，表明印度政府有可用的工具，来合法地利用强制许可。（生物谷bioon.com）
详细英文报道：
Big Pharma was dealt a heavy blow in the battle over compulsory licensing Monday, when India’s patent appeals board ruled that a domestic generic drug maker could continue to make and sell a low-priced copy of Nexavar, a cancer medication patented by Bayer AG. It was the first time the Indian patent authority confirmed that the use of compulsory licensing in India was legal.
Bayer immediately issued a statement saying it would appeal the ruling.
“We strongly disagree with the conclusions of the Intellectual Property Appellate Board,” the company said. “Bayer is committed to protecting its patent for Nexavar and will rigorously continue to defend our intellectual property rights within the Indian legal system.”
Under an international trade agreement known as Trade-Related Aspects of Intellectual Property Rights (TRIPS), countries can issue compulsory licenses on certain drugs that are deemed unaffordable to a large section of their populations. Such licenses have in recent years been issued in Ecuador, Indonesia, Brazil, and Thailand. Last year, the government of India issued a compulsory license for the first time, giving Natco Pharma Ltd. permission to produce and sell copies of Nexavar for a fraction of the cost Bayer charged for the medication.
Bayer challenged the decision to grant a compulsory license to Natco, but on Monday the board ruled that the cancer drug, which fights kidney and liver cancer, should be available at an affordable price to everybody.
In its ruling, the patent appeals board did concede something to Bayer: It ordered Natco to pay Bayer a royalty of 7 percent on sales of generic Nexavar—an increase from the 6 percent royalty that had been set earlier.
This did not assuage the Germany-based company, however. The ruling will not only affect Bayer, but also will have an impact on other brand-name drug manufacturers, who see great market potential in India and other parts of the developing world but are concerned that protection of their intellectual property there is limited.
Monday’s order "weakens the international patent system and endangers pharmaceutical research," Bayer said, noting that patents give it a limited period of marketing exclusivity that help it recover costs associated with the research and development needed to discover new medicines.
Doctors Without Borders/Médecins Sans Frontières (MSF) welcomed the decision, however. “It sets an important precedent,” said Judit Rius, MSF’s access campaign manager in the U.S. “It confirms that the Indian government has tools available to legally grant compulsory licenses.”
MSF is hoping the decision will lead to more compulsory licenses being issued for other drugs that are now patented in India but are too expensive for most patients. “We hope to see licenses for new and important drugs that treat HIV-AIDS, tuberculosis, hepatitis, and malaria,” she said.
Ruit said India’s generic drug makers are known for their ability to produce and market effective generics for a fraction of the cost of the Big Pharma companies that developed the drugs, and noted that the country provides more than 80 percent of all medicines sold in developing nations. “India is the pharmacy of the developing world”, she said.
This is exactly what multinational pharmaceutical companies fear. While this is the first case of a compulsory license in India, drug makers are worried about their patents in India for other reasons. The country has already revoked some patents granted to Pfizer, Roche Holding AG, and Merck & Co., for example. And it rejected Swiss drug maker Novartis’s patent application for the leukemia drug Glivec. Novartis appealed that ruling, and has been awaiting a ruling from the Indian Supreme Court. That ruling could come soon.
(责任编辑：yan.mao)
